A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi

Criteria

Inclusion Criteria:

• Completion of MF-TG101348-001 study

• Diagnosis of myelofibrosis

• At least 18 years of age

Exclusion Criteria:

• Any acute or chronic medical abnormality that may increase the risk associated with study participation